The NTG, the LuMind IDSC Foundation, and an international blue ribbon expert panel produced an advisory on adapting drug formulary committed criteria by States so that adults with Down syndrome (and other intellectual disabilities) can be prescribed FDA approved Alzheimer's disease anti-amyloid immunotherapeutics, once they are authorized for use by adults with Down syndrome. A synopsis of the Panel's report has now been published in Alzheimer's & Dementia, the journal of the Alzheimer's Association.
Exciting progress has been made in the field of Alzheimer's disease treatment. The US Food and Drug Administration (FDA) has provided for accelerated approval for two drugs, aducanumab and lecanemab, for individuals with mild cognitive impairment or early-stage dementia caused by Alzheimer's disease. Expectations are that the FDA will give traditional approval for these drugs in July 2023. Another drug, donanemab, is currently under review, with more expected to follow. However, to prescribe these drugs requires the clinician to address specific eligibility criteria in their patients.
Read more about this project...